



May 11, 2010

Tekmira Pharmaceuticals Conference Call Advisory - First Quarter 2010 Operating Results and Corporate Update

VANCOUVER, BC – Tekmira Pharmaceuticals Corporation (TSX: TKM), a leader in RNA interference (RNAi) therapeutics, announced today that it will hold a conference call and webcast on Thursday May 13, 2010 at 9:00 am Pacific Time (12:00 noon Eastern Time) to discuss first quarter 2010 operating results and to provide a corporate update.

About the Conference Call

To participate in the conference call, please dial 416-340-2218 or 1-866-226-1793. The call will be available for replay until May 27, 2010 by calling 416-695-5800 or 1-800-408-3053 and entering the code 5624011.

The live or archived webcast can also be accessed through the Company's website at www.tekmirapharm.com.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering SNALP and LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

Contact Information for Tekmira Pharmaceuticals Corporation

Investors

Adam Peeler
The Equicom Group
Phone: 416-815-0700 x 225
Email: apeeler@equicomgroup.com

Ian Mortimer
Executive Vice President and Chief Financial Officer
Phone: 604-419-3200

Media

David Ryan
Longview Communications Inc.
Phone: 604-694-6031
Email: dryan@longviewcomms.ca